The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising a histone H3 peptide and an MHC class I protein. Also provided are methods of making and using these constructs.

The subject invention pertains to compositions of novel analogs of red blood cells that are distinguishable from white blood cells in a hematological instrument and processes for manufacturing such analogs. The processes for creating the compositions comprise washing, shrinking, and fixing cells at temperatures at or below room temperature.

The invention generally relates to the field of immunoassays. In particular, the invention relates to use of a calibrator material to calibrate immunoassays for autoantibodies.

Disclosed is a method of characterising and/or separating neutrophils, the method comprises characterising and/or separating the neutrophils into a first population comprising proliferative neutrophils and a second population comprising mature neutrophils, according to the expression of CD101 on the neutrophils. Also disclosed are compositions comprising proliferative neutrophils that are CD10.sup.−CD101.sup.−, and methods of treatment, diagnostic or prognostic using neutrophils thereof, as well as kits for characterising and/or separating proliferative neutrophils based on the expression of CD101 or CD10. In a preferred embodiment, the population of neutrophils may be characterised as proliferative neutrophils if CD10.sup.−CD101.sup.−, as immature neutrophils if CD10.sup.−CD101.sup.+ and as mature neutrophils if CD10.sup.+CD101.sup.+.

The inventors initially participated to the identification of LPIN1 mutations as a cause for massive rhabdomyolysis episodes in children, triggered by febrile illness. The inventors have suggested that TLR9 antagonists would be suitable for the treatment of rhabdomyolysis (WO2017085115). The inventors thus treated 2 patients with lipin-1 disease by a TRL9 antagonist (hydroxychloroquine). They showed that the accumulation of mtDNA in plasma of the two patients before treatment decreases under treatment. When the treatment was stopped, the accumulation of mtDNA reappeared, then normalized when treatment was resumed. Accordingly, the present invention relates to a method for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist comprising determining the amount of mitochondrial DNA (mtDNA) in a blood sample obtained from the patient (e.g. by PCR).

At least one stable isotope reagent is added to each biological sample and standard sample to prepare biological samples for analysis and standard sample for analysis. The quality of the biological samples is evaluated using data of one set of biological samples for analysis composed of a plurality of biological samples for analysis. Besides, the quality of a pretreatment and/or analysis of each set of samples for analysis is evaluated using data obtained by analyzing the standard sample for analysis before and after an analysis of one set of samples for analysis. An abnormality in a chromatograph or mass analyzer used for the analysis of one set of samples is evaluated by the data obtained by analyzing a sample for device evaluation before and after the analysis of one set of samples for analysis. Thus, the quality of data obtained by chromatographic mass spectrometry on biological samples is comprehensively evaluated.

A joint point-of-care testing (POCT) analyzer, and a system comprising an analyzer and a cartridge, for measuring one or more analyte quantities per unit volume of blood and one or more formed element quantities per unit volume of blood, is described. Examples of formed elements of blood are red blood cells and white blood cells, and cell counts are determined by imaging using a two-dimensional multi-channel detector. Examples of analytes are hemoglobin and bilirubin, and hemoglobin and bilirubin concentrations are determined by spectroscopy using a one-dimensional multi-channel detector. Other examples of analytes are electrolytes, and electrolyte concentrations may be determined using biosensors incorporated in the cartridges.

A determination method of a blood sample may include: measuring, with a first coagulation time measurement reagent and a second coagulation time measurement reagent which contain phospholipids at different concentrations, coagulation times of a blood sample of a subject, coagulation times of a normal blood sample, and coagulation times of a mixed sample including the blood sample of the subject and the normal blood sample; acquiring a first index value and a second index value based on the coagulation times; and determining whether the blood sample of the subject is a blood sample containing a direct anticoagulant based on the first index value and the second index value.

A method of assaying an analyte in a sample is disclosed. The method includes having a sample holder with a sample contact area for contacting a sample with an analyte, having a plurality of calibration structures on the sample contact area of the sample holder, imaging a part of the sample contact area that has the calibration structures, and using an algorithm that includes an image, calibration structures in the image, and artificial intelligence and/or machine learning to identify the analyte and/or determine the analyte concentration.

A method of assaying an analyte in a sample is disclosed. The method includes having a sample holder with a sample contact area for contacting a sample with an analyte, having a plurality of calibration structures on the sample contact area of the sample holder, imaging a part of the sample contact area that has the calibration structures, and using an algorithm that includes an image, calibration structures in the image, and artificial intelligence and/or machine learning to identify the analyte and/or determine the analyte concentration.